By Chris Hutching
Friday 22nd February 2002 |
Text too small? |
John Scandrett is leaving his job as commercial development director for the University of Otago where he helped facilitate the commercialisation of Blis Technologies. He will take up a new job as chief executive of Botry-Zen, a company with rights to market an organic control agent against a grape-rotting disease, Botrytis.
Mr Scandrett has worked at Otago for the past 12 years and last year oversaw establishment of a Technology Centre of Innovation, now 80% leased. It was set up to facilitate commercialisation of new research ideas. The university is now seeking a replacement.
It was during the period Blis was being formed that Mr Scandrett met Mr Paterson and his team of professional advisers who have put together the floats of A2 Corporation, Blis, Botry-Zen and Pharma Zen.
Mr Scandrett was approached by Botry-Zen chairman Max Shepherd to take the role of chief executive because of his branding and marketing expertise. (Dr Shepherd is former senior lecturer in biochemistry at Otago and co-founder and chairman of Pharma Zen and a director of Blis.)
Mr Scandrett said his challenge would be to bring the Botry-Zen range of products to the market and develop new opportunities for biological control products.
Waitaki achieved March 31, 2001 revenues of $4.4 million and is forecasting a turnover of $4.9 million and ebit of $750,000. Pharma Zen products will be manufactured at the Waitaki factory in Christchurch and the Waitaki sales team will add them to their range. Waitaki was formed in the 1970s and was bought out by management in 1994, assisted by the Greenstone Fund.
No comments yet
VGL - Potentia withdraws requisition for Special Meeting
November 4th Morning Report
GEN - Completion of Purchase of Premium Funding Business
Fletcher Building Announces Executive Appointment
WCO - Director independence determination
AIA - welcomes Ngahuia Leighton as 'Future Director'
Mercury announces Executive team changes
Fonterra launches Retail Bond Offer
October 29th Morning Report
BIF adds Zincovery to its investment portfolio